Antiseizure Medication in Seizure Networks at Early Acute Brain Injury
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to explore the effect of FDA-approved antiseizure drugs in
the brain connectivity patterns of severe and moderate acute brain injury patients with
suppression of consciousness. The main questions it aims to answer are:
- Does the antiseizure medication reduce the functional connectivity of seizure networks,
as identified by resting state functional MRI (rs-fMRI), within this specific target
population?
- What is the prevalence of seizure networks in patients from the target population, both
with EEG suggestive and not suggestive of epileptogenic activity?
Participants will have a rs-fMRI and those with seizure networks will receive treatment with
two antiseizure medications and a post-treatment rs-fMRI. Researchers will compare the
pretreatment and post-treatment rs-fMRIs to see if there are changes in the participant's
functional connectivity including seizure networks and typical resting state networks.